Diagnostic efficiency of sestamibi gammagraphy and Doppler sonography in the preoperative assessment of breast lesions.
BACKGROUND
It would be desirable to have preoperative methods that allow an adequate selection of patients with breast lesions to rule out breast cancer. The aim of the present study is to evaluate the efficiency of preoperative Sestamibi gammagraphy and Doppler sonography regarding the differential diagnosis of malignancy in breast lesions.


METHODS
A prospective observational study was conducted on 88 consecutive patients with breast lesions. All the patients underwent preoperative Doppler sonography with an echo-enhancing agent and Sestamibi gammagraphy. All the patients had histopathological study of the surgical specimen to compare with the result of the preoperative techniques. These comparisons were done both for the overall series and separately for palpable and non-palpable lesions.


RESULTS
In the overall series results, both tests separately and the two combined, are related significantly to the malignant histological diagnosis (p < 0.001). In palpable lesions, there is a considerable increase in sensitivity, and especially in specificity, attaining 100%, with the combination of both tests. In non-palpable lesions, a relationship was only found between the results of the Sestamibi gammagraphy and the malignant histological diagnosis (93.3%; p < 0.05).


CONCLUSIONS
Sestamibi gammagraphy and Doppler sonography are two efficient exploratory techniques in the preoperative assessment of malignancy in breast lesions, especially for palpable lesions, and this efficiency is greater when they are combined.
Piñero
Antonio
A
Breast Surgery Unit, Department of General Surgery, Virgen de la Arrixaca University Hospital, Murcia, Spain. apm.cg@ono.com
Galindo
Pedro José
PJ
Illana
Julián
J
Nicolás
Francisco
F
Reus
Manuel
M
Hernández
María Dolores
MD
Durán
Isidro
I
Canteras
Manuel
M
Parrilla
Pascual
P
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy; D001706:Biopsy; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000000981:diagnostic imaging / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy; D018275:Carcinoma, Lobular / Q000000981:diagnostic imaging / Q000532:radiotherapy; D005260:Female; D006801:Humans; D008297:Male; D008327:Mammography; D010173:Palpation; D011237:Predictive Value of Tests; D011300:Preoperative Care; D011446:Prospective Studies; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi; D018608:Ultrasonography, Doppler
D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi